โšกYour ready-to-use recruitment solution: IRB-compliant, SEO-optimized website that automatically routes qualified patient leads to your clinical study (14-day free trial, then $44/mo)

NCT05785819RECRUITINGIRB Ready

A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia

Sponsored by Veralox Therapeutics

Quick Self-Assessment

See if you qualify and express your interest

Preparing your pre-screening questions...
๐Ÿ“Š
1 of 60 participants interested
2% interest

Express Your Interest Today

Interested in learning more? Complete the form below.

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Advance Medical Science

    Contribute to groundbreaking research

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel (varies by study)

  • Help Others

    Benefit future patients

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3In-person assessment if eligible
  4. 4Begin participation

About This Study

The purpose of this study is to evaluate the efficacy and safety of VLX-1005, a 12-lipoxygenase (12-LOX) enzyme inhibitor in treating heparin induced thrombocytopenia (HIT). Participants with suspected HIT will receive the usual standard of care, and will be assigned randomly to either VLX-1005 or placebo treatment. The study will measure important outcomes including platelet count, stroke, pulmonary embolus (clot to the lungs) and bleeding.

Who Can Participate

Inclusion Criteria

Adult participants โ‰ฅ 18 years of age. 2. Able to provide informed consent or have informed consent provided on their behalf by a primary caregiver prior to study-related activities being initiated. 3. Recent unfractionated heparin or low-molecular-weight heparin exposure. 4. Qualifying platelet count \< 150 X 10\^9/L and clinical 4T score of โ‰ฅ 4; candidate for argatroban or bivalirudin treatment. 5. Positive PF4-immunoassay (eg, ELISA \[โ‰ฅ 1.0 optical density units\], LIA \[โ‰ฅ 1.0 U/mL\], CLIA \[โ‰ฅ 1.0 U/mL\]). \-

Exclusion Criteria

Treatment with argatroban or bivalirudin for โ‰ฅ 60 hrs prior to randomization. 2. Following discontinuation of heparin, participants cannot be treated with a non-heparin anti-coagulant for โ‰ฅ 60 hours. 3. Current renal dialysis. 4. Pregnant or lactating women. 5. Have participated in any other investigational drug trial within 30 days of dosing or 5 half-lives (whichever is longer) in the current study. 6. In the opinion of the

โ“ Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility during the screening process.

Study Details

๐Ÿ“‹

Study Type

INTERVENTIONAL

๐Ÿ‘ฅ

Target Enrollment

60 participants

โšง

Gender

ALL

๐Ÿข

Sponsor

Veralox Therapeutics

Study Locations

Choose your preferred location or select flexible during enrollment

Unknown

Stanford

California

Location available
View Stanford location page
Unknown

Aurora

Colorado

Location available
View Aurora location page
Unknown

New Haven

Connecticut

Location available
View New Haven location page
Unknown

Washington D.C.

District of Columbia

Location available
View Washington D.C. location page
Unknown

Washington D.C.

District of Columbia

Location available
View Washington D.C. location page
Unknown

Ann Arbor

Michigan

Location available
View Ann Arbor location page
Unknown

Rochester

Minnesota

Location available
View Rochester location page
Unknown

Durham

North Carolina

Location available
View Durham location page
Unknown

Portland

Oregon

Location available
View Portland location page

๐Ÿ“ And 5 more locations available

Frequently Asked Questions

Q:What is a clinical trial?

A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.

Q:Will I be compensated?

Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.

Q:Will I receive a placebo instead of treatment?

When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.

Q:Can I leave a trial if I change my mind?

Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.

Q:How long does a clinical trial last?

Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.

Still have questions? Our study coordinators are here to help.

Ready to Make a Difference?

Express your interest in this groundbreaking clinical trial

๐Ÿ”’ Secure ยท ๐Ÿฅ Expert Care

Looking for Heparin Induced Thrombocytopenia Treatment in Stanford?

Join others in California exploring innovative treatment options through clinical research

Heparin Induced Thrombocytopenia Treatment Options in Stanford, California

If you're searching for Heparin Induced Thrombocytopenia treatment in Stanford, participating in a clinical research study may provide access to innovative approaches under expert medical supervision. This study is actively recruiting participants in Stanford, Aurora, New Haven and surrounding areas.

Clinical trials offer participants the opportunity to receive cutting-edge treatments while contributing to medical research that may help future patients with Heparin Induced Thrombocytopenia. All study-related care is provided at no cost to participants.

Local Sites
3 locations in California
Now Enrolling
Up to 60 participants
Quick Start
Screening available now

Why Consider a Clinical Trial for Heparin Induced Thrombocytopenia?

Potential Benefits

  • โœ“Access to new treatment approaches before public availability
  • โœ“Close monitoring by experienced medical professionals
  • โœ“Study-related care provided at no cost
  • โœ“Contribute to medical research for Heparin Induced Thrombocytopenia

What to Expect

  • โ†’Initial screening to determine eligibility
  • โ†’Regular check-ups and monitoring visits
  • โ†’Possible compensation for time and travel
  • โ†’You can withdraw at any time

Frequently Asked Questions About This Heparin Induced Thrombocytopenia Study

Important Clinical Trial Information

This information is provided for educational purposes and does not constitute medical advice. Clinical trial participation involves potential risks and benefits. Eligibility requirements apply and will be assessed during the screening process.

Study identifier: NCT05785819. For complete study details, visit ClinicalTrials.gov. Always consult with your healthcare provider before making decisions about your medical care or participating in clinical research.